Brain delivery of vasoactive intestinal peptide (VIP) following nasal administration to rats.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  International journal of pharmaceutics

• Publication date

  2003-04-14

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0378-5173(03)00039-5PMID 12672605
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Nasal Absorption Kinetic Behavior of Azetirelin and Its Enhancement by Acylcarnitines in Rats

  2004cited by this paper
• A Novel Formulation of VIP in Sterically Stabilized Micelles Amplifies Vasodilation In Vivo

  2004cited by this paper
• In situ nasal absorption of midazolam in rats.

  2001cited by this paper
• Transport of drugs from the nasal cavity to the central nervous system.

  2000influential reference
• Comparison of cytosine arabinoside delivery to rat brain by intravenous, intrathecal, intraventricular and intraparenchymal routes of administration.

  2000cited by this paper
• Stabilization of vasoactive intestinal peptide by lipids.

  1998cited by this paper
• Nasal absorption kinetics of human growth hormone enhanced by acylcarnitines in rats

  1998cited by this paper
• Differential Effects of Peptide Histidine Isoleucine (PHI) and Related Peptides on Stimulation and Suppression of Neuroblastoma Cell Proliferation

  1998cited by this paper
• CNS Drug Design Based on Principles of Blood‐Brain Barrier Transport

  1998cited by this paper
• Nasal route for direct delivery of solutes to the central nervous system: fact or fiction?

  1998influential reference
• The influence of tonicity and viscosity on the intranasal absorption of salmon calcitonin in rabbits

  1997cited by this paper
• Selective delivery of insulin into the brain: Intraolfactory absorption

  1997influential reference
• Delivery of 125I-NGF to the Brain via the Olfactory Route

  1997cited by this paper
• The Blood‐brain Barrier: Principles for Targeting Peptides and Drugs to the Central Nervous System

  1996influential reference
• Neuroprotective strategy for Alzheimer disease: intranasal administration of a fatty neuropeptide.

  1996influential reference
• Enhancement of Nasal Salmon Calcitonin Absorption by Lauroylcarnitine Chloride in Rats

  1996cited by this paper
• Preparation and characterization of biodegradable poly(isobutylcyano acrylate) nanoparticles with the surface modified by the adsorption of proteins

  1995cited by this paper
• VIP as a cell-growth and differentiation neuromodulator role in neurodevelopment

  1995cited by this paper
• Research advances in Alzheimer's disease and related disorders

  1995cited by this paper
• Effects of formulation variables on nasal epithelial cell integrity: Biochemical evaluations

  1995cited by this paper
• Metabolism of a neurotensin (8–13) analog by intestinal and nasal enzymes, and approaches to stabilize this peptide at these absorption sites

  1995cited by this paper
• In vivo dynamical distribution of 131I-VIP in the rat studied by gamma-camera.

  1994cited by this paper
• Partitioning of vasoactive intestinal polypeptide into lipid bilayers.

  1994influential reference
• Direct drug transport from the rat nasal cavity to the cerebrospinal fluid: the relation to the dissociation of the drug

  1994cited by this paper
• In vitro and in vivo analysis of the mechanism of absorption enhancement by palmitoylcarnitine.

  1994cited by this paper
• Vasoactive intestinal peptide encapsulated in liposomes: effects on systemic arterial blood pressure.

  1994cited by this paper
• Pharmacologic effects in vivo in brain by vector-mediated peptide drug delivery.

  1993cited by this paper
• Characterization of the human liver vasoactive intestinal peptide (VIP) receptor

  1992cited by this paper
• Vasoactive intestinal polypeptide/peptide histidine isoleucine immunoreactive neuron systems in the basal hypothalamus of the rat with special reference to the portal vasculature: an immunohistochemical and in situ hybridization study.

  1991cited by this paper
• The transport of a drug to the cerebrospinal fluid directly from the nasal cavity: the relation to the lipophilicity of the drug.

  1991cited by this paper
• Normal histology of the nasal cavity and application of special techniques.

  1990influential reference
• Distribution and Pharmacology of Vasoactive Intestinal Peptide Receptors in the Brain and Pituitary

  1988cited by this paper
• [mono[125I]iodo-Tyr10,MetO17]-vasoactive intestinal polypeptide. Preparation, characterization, and use for radioimmunoassay and receptor binding.

  1986cited by this paper
• Transport of molecules from nose to brain: transneuronal anterograde and retrograde labeling in the rat olfactory system by wheat germ agglutinin-horseradish peroxidase applied to the nasal epithelium.

  1985cited by this paper
• Absorption of drugs from the nasal mucosa of rat

  1981cited by this paper
• Vasoactive intestinal polypeptide induces glycogenolysis in mouse cortical slices: a possible regulatory mechanism for the local control of energy metabolism.

  1981cited by this paper
• Vasoactive intestinal polypeptide.

  1980cited by this paper
• Cerebral circulatory and metabolic effects of vasoactive intestinal polypeptide.

  1980cited by this paper
• Vasoactive intestinal polypeptide: measurement, distribution and putative neurotransmitter function.

  1979cited by this paper
• Vasoactive intestinal peptide in man: pharmacokinetics, metabolic and circulatory effects.

  1978influential reference
• Polypeptide with Broad Biological Activity: Isolation from Small Intestine

  1970cited by this paper

• Intranasal Galanin (1–15) modulates alcohol self-administration and depressive-like behavior in rats and shows a favorable safety profile

  2025cites this paper
• Genome‐Wide Translatome Analysis Following Low‐Dose Ketamine to Reveal Novel Targets for Antidepressant Treatment

  2025cites this paper
• Next-generation lipid nanocarriers for Parkinson's therapy: nose-to-brain innovations and clinical prospects.

  2025cites this paper
• Lactobacilli cell-free supernatants: Potential green and natural enhancers for nose-to-brain delivery of small hydrophilic molecules

  2024cites this paper
• Refinement of intranasal delivery in rats: A cadaveric study

  2024cites this paper
• CREB-regulated transcription during glycogen synthesis in astrocytes

  2024cites this paper
• Exploring the Potential of Nasal Drug Delivery for Brain Targeted Therapy: A Detailed Analysis

  2024cites this paper
• Intranasal nanoparticulate delivery systems for neurodegenerative disorders: a review.

  2023cites this paper
• Effect of mucociliary clearance on the particulate airflow inside the nasal sinus and its role in increasing the residence time and absorption of drugs inside the upper respiratory pathway

  2023cites this paper
• Investigating the Targeting Power to Brain Tissues of Intranasal Rasagiline Mesylate-Loaded Transferosomal In Situ Gel for Efficient Treatment of Parkinson’s Disease

  2023cites this paper
• Intranasal administration of olanzapine has beneficial outcome in a rat activity-based anorexia model.

  2023cites this paper
• Intranasal Atomization of Ketamine, Medetomidine and Butorphanol in Pet Rabbits Using a Mucosal Atomization Device

  2023cites this paper
• Nose-to-Brain (N2B) Delivery: An Alternative Route for the Delivery of Biologics in the Management and Treatment of Central Nervous System Disorders

  2023cites this paper
• Enhancing Antibody Exposure in the Central Nervous System: Mechanisms of Uptake, Clearance, and Strategies for Improved Brain Delivery

  2023cites this paper
• Current Approaches to Facilitate Improved Drug Delivery to the Central Nervous System.

  2022cites this paper
• Fear extinction induced by activation of PKA ameliorates anxiety-like behavior in PTSD mice.

  2022cites this paper
• In Vitro Evaluation of Curcumin- and Quercetin-Loaded Nanoemulsions for Intranasal Administration: Effect of Surface Charge and Viscosity

  2022cites this paper
• Brain barriers and their potential role in migraine pathophysiology

  2022cites this paper
• Biodistribution analysis of an intranasal-delivered peptide by the nanoSPECT/CT imaging

  2022cites this paper
• Targeting the interaction of GABAB receptors with CaMKII with an interfering peptide restores receptor expression after cerebral ischemia and inhibits progressive neuronal death in mouse brain cells and slices

  2022cites this paper
• Using the Intranasal Route to Administer Drugs to Treat Neurological and Psychiatric Illnesses: Rationale, Successes, and Future Needs

  2022cites this paper
• Polymeric Nanoparticles in Brain Cancer Therapy: A Review of Current Approaches

  2022cites this paper
• Nose-to-Brain Delivery of Therapeutic Peptides as Nasal Aerosols

  2022cites this paper
• Advancements in drug delivery methods for the treatment of brain disease

  2022cites this paper
• Intranasal administration of fingolimod (FTY720) attenuates demyelination area in lysolecithin-induced demyelination model of rat optic chiasm.

  2022cites this paper
• A targeted extracellular vesicles loaded with montelukast in the treatment of demyelinating diseases.

  2022cites this paper
• Using PCG-Arginine nanoparticle mediated intranasal delivery of dynorphin A (1–8) to improve neuroprotection in MCAO rats

  2021cites this paper
• Intranasal Drug Delivery: Novel Delivery Route for Management of Parkinson’s and Depression Neurological Disorders

  2021cites this paper
• Development and Patient Experience Evaluation of a Gentle Atomizer for Nasal Drug Delivery

  2021cites this paper
• Lavender aromatherapy: A systematic review from essential oil quality and administration methods to cognitive enhancing effects

  2021cites this paper
• Intranasal drug delivery for treatment of Alzheimer’s disease

  2021cites this paper
• Improving the Utility of a Dynorphin Peptide Analogue Using Mannosylated Glycoliposomes

  2021cites this paper
• Development and evaluation of inhalable composite niclosamide-lysozyme particles: A broad-spectrum, patient-adaptable treatment for coronavirus infections and sequalae

  2021cites this paper
• Dynorphin A (1-8) inhibits oxidative stress and apoptosis in MCAO rats, affording neuroprotection through NMDA receptor and κ-opioid receptor channels.

  2021cites this paper
• Intranasal Low-Dose Naltrexone Against Opioid Side Effects: A Preclinical Study

  2020influential citation
• Implications of VIP and PACAP in Parkinson's disease: what do we know so far?

  2020cites this paper
• VIPergic neuroprotection in epileptogenesis: challenges and opportunities.

  2020cites this paper
• Comparative study of oral and intranasal puerarin for prevention of brain injury induced by acute high-altitude hypoxia.

  2020cites this paper
• Tailoring solulan C24 based niosomes for transdermal delivery of donepezil: In vitro characterization, evaluation of pH sensitivity, and microneedle-assisted Ex vivo permeation studies

  2020cites this paper
• Broad-Spectrum, Patient-Adaptable Inhaled Niclosamide-Lysozyme Particles are Efficacious Against Coronaviruses in Lethal Murine Infection Models

  2020cites this paper
• Nanoparticles Based Intranasal Delivery of Drug to Treat Alzheimer's Disease: A Recent Update.

  2020cites this paper
• Therapeutic effect of vasoactive intestinal peptide on form-deprived amblyopic kittens

  2019cites this paper
• Evaluation of intranasal delivery route of drug administration for brain targeting.

  2018cites this paper
• High-yielding 18F radiosynthesis of a novel oxytocin receptor tracer, a probe for nose-to-brain oxytocin uptake in vivo

  2018cites this paper
• Intranasal delivery of stem cell-based therapies for the treatment of brain malignancies

  2018cites this paper
• Assessing the feasibility of intranasal radiotracer administration for in brain PET imaging

  2018cites this paper
• Nose‐to‐brain drug delivery: An update on clinical challenges and progress towards approval of anti‐Alzheimer drugs

  2018cites this paper
• Intranasal VIP safely restores volume to multiple grey matter nuclei in patients with CIRS

  2017cites this paper
• Stimuli-Responsive Systems with Diverse Drug Delivery and Biomedical Applications: Recent Updates and Mechanistic Pathways.

  2017cites this paper
• Nose-to-brain peptide delivery - The potential of nanotechnology.

  2017cites this paper
• Drug Vectoring Systems To Target Drug Delivery Using Nanotechnologies

  2017cites this paper
• Challenges of the Nose-to-Brain Route

  2017cites this paper
• Thermosensitive PLA based nanodispersion for targeting brain tumor via intranasal route.

  2016cites this paper
• Intranasal Delivery of Recombinant NT4-NAP/AAV Exerts Potential Antidepressant Effect

  2016cites this paper
• Recent Updates in the Formulation Strategies to Enhance the Bioavailability of Drugs Administered via Intranasal Route

  2016cites this paper
• Application of RPMI 2650 as a cell model to evaluate solid formulations for intranasal delivery of drugs.

  2016cites this paper
• Visualization and Quantitative Assessment of the Brain Distribution of Insulin through Nose-to-Brain Delivery Based on the Cell-Penetrating Peptide Noncovalent Strategy.

  2016cites this paper
• Treatment of neurological disorders by introducing mRNA in vivo using polyplex nanomicelles.

  2015cites this paper
• Optimization, characterization and evaluation of chitosan-tailored cubic nanoparticles of clotrimazole.

  2015cites this paper
• Interrogating the role of splicing factors in Huntington’s Disease

  2015cites this paper
• Nano-ropinirole for the management of Parkinsonism: blood–brain pharmacokinetics and carrier localization

  2015cites this paper
• Harnessing the capacity of cell-penetrating peptides for drug delivery to the central nervous system.

  2014cites this paper
• Influence of active efflux transport on the distribution of targeted agents to brain tumors

  2014cites this paper
• Strategie formulative per la veicolazione nasale di farmaci

  2014cites this paper
• NASAL DRUG DELIVERY SYSTEM: AN EMERGING APPROACH FOR BRAIN TARGETING

  2014cites this paper
• Transferrin receptor antibody-modified α-cobrotoxin-loaded nanoparticles enable drug delivery across the blood–brain barrier by intranasal administration

  2013cites this paper
• Nanomedicines as cancer therapeutics: current status.

  2013cites this paper
• Activatable cell penetrating peptide-conjugated nanoparticles with enhanced permeability for site-specific targeting delivery of anticancer drug.

  2013cites this paper
• Recent Advances in Brain Delivery Researches for Biopharmaceuticals

  2013cites this paper
• Routes of Delivery for Biological Drug Products

  2013cites this paper
• The role of organic cation transporters in the nasal uptake and brain distribution of organic cation substrates

  2013cites this paper
• Brain pharmacokinetics of neurotoxin-loaded PLA nanoparticles modified with chitosan after intranasal administration in awake rats

  2013cites this paper
• Characterization of Neuropeptide S (NPS) in view of its potential as a novel anxiolytic therapy for anxiety disorders

  2012cites this paper
• Intranasal treatment of neurodegenerative diseases and stroke.

  2012cites this paper
• Intranasally Administered Neuropeptide S (NPS) Exerts Anxiolytic Effects Following Internalization Into NPS Receptor-Expressing Neurons

  2012cites this paper
• Solanum tuberosum lectin-conjugated PLGA nanoparticles for nose-to-brain delivery: in vivo and in vitro evaluations

  2012cites this paper
• MULTIFUNCTIONAL NANOCARRIERS ENCAPSULATING ANTI-ALZHEIMER DRUG FOR NASAL DELIVERY TO CENTRAL NERVOUS SYSTEM

  2012cites this paper
• Peptides as therapeutics with enhanced bioactivity.

  2012cites this paper
• Drug development of intranasally delivered peptides.

  2012cites this paper
• Effects of manganese injected into rat nostrils: implications for in vivo functional study of olfaction using MEMRI.

  2012cites this paper
• Intranasal administration of PACAP: uptake by brain and regional brain targeting with cyclodextrins.

  2012cites this paper
• Intranasal treatment of neurodegenerative diseases and stroke

  2012cites this paper
• Intranasal Administration of PACAP: Uptake by Brain and Brain Region Targeting with Cyclodextrins

  2012cites this paper
• Nose-to-Brain Transport Pathways of Wheat Germ Agglutinin Conjugated PEG-PLA Nanoparticles

  2011cites this paper
• Strategies to convert PACAP from a hypophysiotropic neurohormone into a neuroprotective drug.

  2011cites this paper
• Neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) slows down Alzheimer's disease-like pathology in amyloid precursor protein-transgenic mice

  2011cites this paper
• Intranasal delivery of therapeutic proteins for neurological diseases

  2011cites this paper
• Low molecular weight protamine-functionalized nanoparticles for drug delivery to the brain after intranasal administration.

  2011cites this paper
• Odorranalectin-conjugated nanoparticles: preparation, brain delivery and pharmacodynamic study on Parkinson's disease following intranasal administration.

  2011cites this paper
• Development and evaluation of olanzapine-loaded PLGA nanoparticles for nose-to-brain delivery: in vitro and in vivo studies.

  2011cites this paper
• Bioresponsive nanoparticles based on poly(amidoamine)s for protein delivery

  2011cites this paper
• Microemulsions and Nanoemulsions for Targeted Drug Delivery to the Brain

  2011cites this paper
• Colloidal nanocarriers: a review on formulation technology, types and applications toward targeted drug delivery.

  2010cites this paper
• Nasal Route: A Potential Alternative for Antiparkinsonism Drug Delivery

  2010cites this paper
• Intranasal delivery to the central nervous system: mechanisms and experimental considerations.

  2010influential citation
• Brain delivery of proteins by the intranasal route of administration: a comparison of cationic liposomes versus aqueous solution formulations.

  2010cites this paper
• Intranasal delivery of macromolecules to the rodent brain via olfactory pathways.

  2009cites this paper
• University of Groningen A new minimal-stress freely-moving rat model for preclinical studies on intranasal administration of CNS drugs Stevens, Jasper; Suidgeest,

  2009cites this paper
• A New Minimal-Stress Freely-Moving Rat Model for Preclinical Studies on Intranasal Administration of CNS Drugs

  2009cites this paper
• Intranasal Targeting of Neuropeptides to the Central Nervous System: Evaluation of Pharmacokinetics, Pharmacodynamics, and a Novel Vasoconstrictor Formulation

  2009cites this paper